- Conditions
- Hyperlipidemia
- Interventions
- K-312 10 mg QD, K-312 25 mg QD, K-312 50 mg QD, K-312 100 mg QD, K-312 200 mg QD, K-312 400 mg QD, Placebo
- Drug · Other
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Glendale, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–720
of 3,785
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Basal Cell Carcinoma in Basal Cell Nevus Syndrome
- Interventions
- ASN-002
- Biological
- Lead sponsor
- Ascend Biopharmaceuticals Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Infections, Pneumonia
- Interventions
- Ceftaroline fosamil, IV Ceftriaxone and Vancomycin
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 2 Months to 18 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 13
- States / cities
- Long Beach, California • Oakland, California • Orange County, California + 10 more
- Conditions
- Esophagogastric Junction Disorder
- Interventions
- Pneumatic dilation
- Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Opioid Use Disorder
- Interventions
- RBP-6000, Suboxone
- Drug
- Lead sponsor
- Indivior Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Hepatic Impairment
- Interventions
- AZD2389
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 5
- States / cities
- Chandler, Arizona • Rialto, California • Miami Lakes, Florida + 2 more
- Conditions
- Cystic Fibrosis
- Interventions
- TEZ, IVA, VX-440, Matched Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Palo Alto, California • San Francisco, California + 18 more
- Conditions
- Kidney Transplant Rejection
- Interventions
- Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox)
- Diagnostic Test · Other
- Lead sponsor
- CareDx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 54 more
- Conditions
- Insulin Sensitivity
- Interventions
- Ultrasound, OGTT with unlabeled glucose and liver NMR, OGTT with carbon-13 labeled glucose and liver NMR, CGM glucose reading, HEC - Hyperinsulinemic-Euglycemic-Clamp
- Device · Diagnostic Test
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
- Interventions
- AB308, Zimberelimab
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Jacksonville, Florida • Goshen, Indiana + 12 more
- Conditions
- Cancer
- Interventions
- recombinant human thrombopoietin, carboplatin, etoposide, ifosfamide, G-CSF
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2005
- U.S. locations
- 23
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 16 more
- Conditions
- Brain Injury Traumatic Mild, Brain Injuries, Brain Injuries, Acute, Head Injury With Intracranial Hemorrhage, Head Injury Trauma, Brain Injury Traumatic Focal With Loss of Consciousness, Skull Fractures, Diffuse Axonal Injury, Intracranial Hemorrhages, Head Injury
- Interventions
- Validated Questionnaires, Questionnaires, Clinician / Medical Record Variables
- Behavioral · Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 2,592 participants
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Sacramento, California • Philadelphia, Pennsylvania • Providence, Rhode Island + 3 more
- Conditions
- Covid19
- Interventions
- sotrovimab
- Biological
- Lead sponsor
- Vir Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 316 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 10
- States / cities
- Riverside, California • Atlantis, Florida • Edgewater, Florida + 7 more
- Conditions
- Radiation Retinopathy
- Interventions
- 0.5 mg ranibizumab, Targeted Retinal Photocoagulation (TRP)
- Drug · Procedure
- Lead sponsor
- Greater Houston Retina Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 4
- States / cities
- Dallas, Texas • Houston, Texas • Katy, Texas + 1 more
- Conditions
- Pediatric Solid Tumor, Neuroblastoma
- Interventions
- B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Robbie Majzner
- Other
- Eligibility
- 9 Months to 30 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Oncology
- Interventions
- Entospletinib
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
- Conditions
- Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Non-squamous Cell Lung Cancer
- Interventions
- PM01183 + paclitaxel +/- bevacizumab
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Interventions
- mitoxantrone hydrochloride, etoposide, cytarabine, selinexor, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- Alice Mims
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Prostate Cancer
- Interventions
- ABT-751
- Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Crohn's Disease
- Interventions
- Guselkumab
- Drug
- Lead sponsor
- Janssen-Cilag Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- San Francisco, California • Chicago, Illinois • St Louis, Missouri + 1 more
- Conditions
- Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
- Interventions
- MOR00208, lenalidomide, Correlative Studies
- Biological · Drug · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms, Prostatic Neoplasms, Prostatic Diseases
- Interventions
- Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only)
- Drug · Diagnostic Test
- Lead sponsor
- Blue Earth Therapeutics Ltd
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 5
- States / cities
- Miami, Florida • Atlanta, Georgia • Omaha, Nebraska + 1 more
- Conditions
- Frontotemporal Dementia, FTD, FTD-GRN, Dementia, Frontotemporal
- Interventions
- Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101
- Procedure · Genetic
- Lead sponsor
- AviadoBio Ltd
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 3
- States / cities
- Columbus, Ohio • Nashville, Tennessee • Houston, Texas
- Conditions
- Obesity, Overweight
- Interventions
- NNC0113-5840, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland